Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (COVID-19), in
BRUSSELS: The European Commission said on Thursday it had signed a contract with U.S. drugmaker Gilead for the supply of up to 500,000 treatment courses for remdesivir, sharply increasing the supply of the COVID-19 treatment in Europe.
The Commission, which has overseen joint purchases of vaccines in the European Union, said there were 36 signatories to the agreement, including all EU countries, six Balkan candidate and potential EU members, Britain and the other European Economic Area countries Iceland, Liechtenstein and Norway.
